CPT code 87593 represents an amplified nucleic acid probe test performed on patient specimens (for example, skin-lesion swabs) to detect orthopoxvirus nucleic acids, including monkeypox virus. This molecular diagnostic code is nationally relevant for public health surveillance, outbreak response, and clinical diagnosis of suspected orthopoxvirus infections. Laboratories use this test to confirm viral presence and guide infection-control actions.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for use of the test, typical sites of service, and the kinds of benchmarks and policy considerations that affect coverage and billing for molecular infectious-disease diagnostics. The publication addresses reimbursement benchmarks, common billing modifiers encountered in practice, and coding considerations relevant to laboratory and hospital billing workflows.

The content is intended to inform laboratory administrators, billing professionals, and policy analysts about how CPT code 87593 is used in practice, what payers commonly cover, and where to look for policy updates that affect testing for orthopoxviruses. Data not available in the input is noted where applicable.